Patents by Inventor Douglas J. Hilton
Douglas J. Hilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080274973Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: July 1, 2008Publication date: November 6, 2008Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20080166730Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: October 23, 2007Publication date: July 10, 2008Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 7279557Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: November 17, 2004Date of Patent: October 9, 2007Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 7220828Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 10, 1998Date of Patent: May 22, 2007Assignee: Zenyth Operations Pty LtdInventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Jian-Guo Zhang, Alison Farley, Warren Alexander, Steven Rakar, Yasufumi Kikuchi, Tetsuo Kojima, Masatsugu Maeda, Louis Fabri, Andrew Nash
-
Patent number: 7192576Abstract: The present invention relates generally to a biologically active complex comprising at least two heterologous molecules. More particularly, the biologically active complex of the present invention comprises at least two polypeptides or parts, fragments, truncates or protease-activated forms of one or more of the polypeptides wherein the complex alone or in association with a receptor, ligand or other molecule facilitates proliferation, differentiation and/or survival of a cell. The identification of the biologically active complex of the present invention permits the assay for agonists and antagonists of the formation of the biologically active complex as well as therapeutic and diagnostic reagents based on the biologically active complex or interaction between the biologically active complex and a receptor, ligand or other molecule.Type: GrantFiled: October 6, 2000Date of Patent: March 20, 2007Assignee: Zenyth Operations Pty Ltd.Inventors: Andrew Nash, Kim Maree Jachno, Louis J. Fabri, Kate Reid, Perry F. Bartlett, Douglas J. Hilton, Yasuhiko Nakata, Masakazu Hasegawa
-
Patent number: 7078174Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.Type: GrantFiled: December 21, 1999Date of Patent: July 18, 2006Assignee: The Walter & Eliza Hall Institute of Medical ResearchInventors: Tracy Ann Willson, Richard John Simpson, Alison Mary Farley, Sandra Elaine Nicholson, Jian-Guo Zhang, Manuel Baca, Nicos A. Nicola, Douglas J. Hilton, Warren Scott Alexander, Donald Metcalf
-
Patent number: 7049418Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: July 19, 2001Date of Patent: May 23, 2006Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 6911530Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: October 13, 2000Date of Patent: June 28, 2005Assignee: Amrad Operations, Pty., Ltd.Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6905842Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: October 31, 1997Date of Patent: June 14, 2005Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20020147307Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction.Type: ApplicationFiled: July 19, 2001Publication date: October 10, 2002Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20020090682Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: November 7, 2001Publication date: July 11, 2002Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20020045741Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: March 10, 1998Publication date: April 18, 2002Inventors: TRACY WILLSON, NICOS A. NICOLA, DOUGLAS J. HILTON, DONALD METCALF, JIAN GUO ZHANG
-
Patent number: 6323317Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: April 30, 1999Date of Patent: November 27, 2001Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 5443825Abstract: Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.Type: GrantFiled: September 22, 1992Date of Patent: August 22, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5427925Abstract: The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.Type: GrantFiled: May 6, 1993Date of Patent: June 27, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5187077Abstract: A leukaemia-inhibitory factor (LIF) is disclosed, together with a method of preparation of LIF in essentially pure form. Nucleotide and amino acid sequences are disclosed, together with recombinant DNA moleclues and host cells for production of polypeptides having LIF activity.Type: GrantFiled: December 9, 1988Date of Patent: February 16, 1993Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5166065Abstract: The present invention relates generally to the use of leukaemia inhibitory factor (LIF) in the maintenance and derivation of embryonic stem (ES) cells in culture. The ES cells are maintained and/or derived from animal embryos by culturing said cells or embryos in a culture medium containing an effective amount of LIF for a time and under conditions sufficient to maintain and/or derive said ES cells. The ES cells may be passaged in LIF and used to make chimaeric animals.Type: GrantFiled: May 31, 1990Date of Patent: November 24, 1992Assignee: Amrad Corporation LimitedInventors: Robert L. Williams, Nicholas M. Gough, Douglas J. Hilton